Premium
Integrating cancer genomics and proteomics in the post‐genome era
Author(s) -
Hanash Samir M.,
Bobek Miroslav P.,
Rickman David S.,
Williams Tom,
Rouillard Jean Marie,
Kuick Rork,
Puravs Eric
Publication year - 2002
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/1615-9861(200201)2:1<69::aid-prot69>3.0.co;2-8
Subject(s) - proteomics , biology , computational biology , genomics , dna microarray , genome , transcriptome , gene , complementary dna , oligonucleotide , human genome , microbiology and biotechnology , genetics , gene expression
The dawn of the post‐genome era is leading to extraordinary opportunities in biomedicine. Our group has embarked on a major effort to integrate genomics, transcriptomics and proteomics for the profiling of tumor tissues, an approach we refer to as operomics. Our major goals are the molecular classification of tumors and the identification of markers for the early detection of cancer. Molecular analyses of tumors rely on microdissected tissues, which are simultaneously investigated for genomic, transcriptomic and proteomic changes. Genomic alterations in tumor cells being investigated include deletions, amplifications and methylation changes across the entire genome as well as point mutations in specific genes. Expression analysis at the RNA level is being undertaken using oligonucleotide and cDNA based microarrays. An important aspect of our approach is the large‐scale identification and quantitative analysis of tumor proteins in whole cell lysates as well as in protein compartments. Protein separation strategies include two‐dimensional polyacrylamide gel electrophoresis and liquid chromatography. Specific protein subsets, of interest include membrane proteins, secreted proteins and antigenic proteins as sources of biomarkers for early detection of cancer. Our current approach is illustrated with findings stemming from our studies of human gliomas.